Lee JW, et al. - In this systematic review and Bayesian network meta-analysis (NMA) of 219 trials involving 228,710 individuals, experts contrasted exacerbation, mortality, and adverse events among all regular inhaled drug classes, including inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting beta-agonist (LABA), LAMA/LABA, ICS/LABA, LAMA, LABA, ICS, and placebo. In the NMA, for decreasing total aggravations and all-cause mortality, ICS/LAMA/LABA was the most efficient treatment. In comparison with placebo, ICS/LABA also decreases all-cause mortality in this NMA. All drug classes decreased the exacerbation risk in comparison with the placebo. Findings imply that for stable COPD individuals, triple therapy could possibly be the superior alternative in terms of decreasing exacerbation and all-cause mortality.